September 11, 2025

Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial.

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Randomized trial shows improved PASI and IGA responses in Chinese patients with psoriasis, indicating guselkumab's effectiveness.

Guselkumab significantly improved PASI 90 response in 82.4% of patients by week 16, compared to 2.0% with placebo.
The placebo group showed later improvements after switching to guselkumab, with PASI 90 at 80.2% by week 48.
This was a randomized, double-blind, placebo-controlled trial assessing guselkumab's effects on psoriasis.
Guselkumab is effective with a favorable safety profile in Chinese patients, with low serious adverse events.

Huang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark